|1.||Moyer, Michelle: 3 articles (12/2008 - 01/2002)|
|2.||Ohno, Kinji: 2 articles (01/2014 - 03/2004)|
|3.||Maddison, Paul: 2 articles (12/2012 - 01/2011)|
|4.||Pollarine, Jennifer: 2 articles (12/2008 - 01/2008)|
|5.||van Lunteren, Erik: 2 articles (01/2008 - 01/2002)|
|6.||Maddison, P: 2 articles (01/2005 - 01/2003)|
|7.||Newsom-Davis, J: 2 articles (01/2005 - 01/2003)|
|8.||Taus, C: 2 articles (01/2002 - 01/2001)|
|9.||Solari, A: 2 articles (01/2002 - 01/2001)|
|10.||Giuliani, G: 2 articles (01/2002 - 01/2001)|
|1.||Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome)
09/01/1998 - "3,4-Diaminopyridine (3,4-DAP) is known to be beneficial in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). "
12/07/1989 - "We conclude that 3,4-diaminopyridine, either alone or in conjunction with other therapies, may be useful in the treatment of Lambert-Eaton myasthenic syndrome."
11/01/2009 - "The purpose of this study was to investigate the clinical and electrophysiological efficacy of 3,4-diaminopyridine (DAP) in patients with Lambert-Eaton myasthenic syndrome (LEMS) in a randomized, double-blind, cross-over drug trial. "
08/01/1998 - "Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome."
01/01/2011 - "Four controlled trials of 3,4-diaminopyridine compared with placebo in a total of 54 participants with Lambert-Eaton myasthenic syndrome were eligible: three cross-over trials and one parallel group. "
06/30/1985 - "3,4-Diaminopyridine (3,4-DAP), a compound which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type F-treated muscles. "
01/01/1983 - "However, 3,4-diaminopyridine, an agent which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type B-treated muscles.(ABSTRACT TRUNCATED AT 250 WORDS)"
02/01/2001 - "Data suggesting that BoNT/E can enter BoNT/A-treated preparations was obtained by findings that 3,4-diaminopyridine, which readily reversed muscle paralysis after BoNT/A exposure, lost this ability within 1 h of BoNT/E addition. "
11/01/2012 - "Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations."
10/01/2000 - "The ability of 3,4-diaminopyridine (3,4-DAP) to antagonize muscle paralysis following local injection of botulinum neurotoxin A (BoNT/A) complex was evaluated in the in situ rat extensor digitorum longus (EDL) preparation. "
01/01/2011 - " trials of 3,4-diaminopyridine reported significant improvement in the primary outcome, muscle strength score, or myometric limb measurement for between hours and a week following treatment, and significant improvement in resting compound muscle action potential (CMAP) amplitude following 3,4-diaminopyridine, compared with placebo.A meta-analysis of the primary endpoint showed Quantitative Myasthenia Gravis (QMG) muscle score assessed between three and eight days was likely to improve by a mean of 2.44 points (95% confidence interval 3.6 to 1.22). "
01/01/1985 - "Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine."
11/01/1996 - "Eleven patients with congenital and five with juvenile myasthenia gravis, aged 5 to 24 years, were given 3,4-diaminopyridine in a double-blind, placebo-controlled, crossover study. "
06/21/1993 - "3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis."
04/01/2012 - "3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis."
01/01/2009 - "He started taking 3,4-diaminopyridine and his muscle weakness improved dramatically, and he was eventually able to walk finally. "
04/01/1995 - "Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations."
05/15/2013 - "Muscle weakness can be improved upon treatment with pyridostigmine, a cholinesterase inhibitor, or with 3,4-diaminopyridine, which increases the release of ACh quanta. "
08/21/2002 - "The present study compares two methods of preparation of microparticles of 3,4-diaminopyridine (3,4-DAP) for the treatment for multiple sclerosis and Lambert-Eaton myasthenia syndrome. "
04/01/1990 - "Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis."
05/01/1998 - "The findings suggest that 3,4-diaminopyridine may play a role in the symptomatic treatment of fatigue in multiple sclerosis. "
11/01/1994 - "Our data suggest that, concerning both efficacy and side effects, 4-aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis."
11/01/1994 - "4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis."
|2.||Pyridostigmine Bromide (Pyridostigmine)
|3.||4-Aminopyridine (4 Aminopyridine)
|4.||Intravenous Immunoglobulins (IVIG)
|6.||Botulinum Toxins (Botulinum Toxin)
|7.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|8.||Brain-Derived Neurotrophic Factor (BDNF)
|2.||Drug Therapy (Chemotherapy)